A5101945025- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Lanthanide and Transition Metal Complexes
- Economic and Financial Impacts of Cancer
- Electron Spin Resonance Studies
- SARS-CoV-2 and COVID-19 Research
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biomedical Text Mining and Ontologies
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Advanced MRI Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Escherichia coli research studies
- Chronic Myeloid Leukemia Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer Immunotherapy and Biomarkers
- Stellar, planetary, and galactic studies
- Astro and Planetary Science
University of North Carolina at Chapel Hill
2020-2024
UNC Lineberger Comprehensive Cancer Center
2021-2024
University of Calgary
2023
Inserm
2023
Université de Bretagne Occidentale
2023
Vanderbilt University Medical Center
2015-2020
Vanderbilt University
2016-2020
Vanderbilt-Ingram Cancer Center
2017
University of Chicago
2013
Jagiellonian University
2013
<h3>Importance</h3> COVID-19 is a life-threatening illness for many patients. Prior studies have established hematologic cancers as risk factor associated with particularly poor outcomes from COVID-19. To our knowledge, no beneficial role anti–COVID-19 interventions in this at-risk population. Convalescent plasma therapy may benefit immunocompromised individuals COVID-19, including those cancers. <h3>Objective</h3> evaluate the association of convalescent treatment 30-day mortality...
Monoclonal antibodies (mAb) targeting PD-1/PD-L1 have revolutionized melanoma treatment, yet data regarding effectiveness and tolerability across age groups is limited. We sought to determine the impact of on overall survival (OS), progression-free (PFS), rates immune-mediated toxicities in patients treated with anti-PD-1/anti-PD-L1 mAb at two academic medical centers.We retrospectively collected all metastatic anti-PD-1/PD-L1 between May 2009 April 2015. used Kaplan-Meier Cox regression...
Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to worse outcomes associated during the pandemic. We sought evaluate clinical characteristics and patients who developed breakthrough after 2 or 3 doses mRNA vaccines.
Abstract Clinical trials to ameliorate hypoxia as a strategy relieve the radiation resistance it causes have prompted need assay precise extent and location of in tumors. Electron paramagnetic resonance oxygen imaging (EPR O2 imaging) provides noninvasive means address this need. To obtain preclinical proof-of-principle that EPR images could predict control, we treated mouse tumors at or near doses required achieve 50% control (TCD50). Mice with FSa fibrosarcoma MCa4 carcinoma were subjected...
Summary Immunomodulatory drugs (IMiDs) have improved survival of patients with multiple myeloma (MM) and comprise the therapeutic backbone at all phases therapy. Although well‐tolerated, IMiDs increase rates venous thromboembolism (VTE). In this phase IV, single‐arm pilot study, fifty MM on received apixaban 2·5 mg orally twice daily for primary prevention VTE were prospectively monitored six months. The safety outcomes major haemorrhage clinically relevant non‐major over efficacy outcome...
BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAFV600 -mutated melanomas. Acquired resistance occurs most patients, with numerous diverse drivers. We obtained pretreatment progression biopsies from a patient who progressed on dabrafenib trametinib. In addition to preserved BRAFV600E mutation, an internal deletion (rearrangement) of was observed the sample. This involved exons 2-8, which includes Ras-binding domain, is analogous previously documented fusions splice...
Summary Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those hematologic malignancy. We evaluated the association of convalescent treatment 30-day mortality in hospitalized adults malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, was associated improved (hazard ratio, 0.60; 95% CI, 0.37-0.97). This remained significant after...
ABSTRACT Background Initial insights into oncology clinical trial outcomes are often gleaned manually from conference abstracts. We aimed to develop an automated system extract safety and efficacy information study abstracts with high precision fine granularity, transforming them computable data for timely decision-making. Methods collected key conferences PubMed (2012-2023). The SEETrials was developed four modules: preprocessing, prompt modeling, knowledge ingestion postprocessing....
Background and objectives: Light chain (AL) amyloidosis frequently involves the kidney, causing significant morbidity mortality. A pathologic scoring system with prognostic utility has not been developed. We hypothesized that extent of amyloid deposition degree scarring injury on kidney biopsy, could provide value, aimed to develop tools based these features.Methods: This is a case-control study 39 patients treated for AL biopsy-proven involvement at large academic medical center. Our novel...
Primary central nervous system lymphoma (PCNSL) patients have a poorer prognosis than systemic lymphoma. Gain-of-function MYD88 c.794T > C (p. L265P) mutation and programed cell death-1 (PD-1) pathway alterations are potential targetable pathways. Our study objective was to determine the clinicopathologic correlates of PD-1 in PCNSL impact Epstein–Barr virus (EBV) infection. We studied 53 cases including 13 EBV-associated (EBVpos) PCNSL, 49% harbored mutation, none seen EBVpos PCNSL. protein...
Due to decades of nonstandardized approaches the naming chemotherapy regimens, representation in electronic health records and secondary systems is highly variable. This hampers efforts understand patterns usage at population level. In this article, we describe a proposal for rules standardize nomenclature regimens illustrate applications these rules.Through our experience with building HemOnc.org, which has been under construction since 2011, formulated set guidelines recommendations...
PURPOSE Electronic health records (EHRs) are created primarily for nonresearch purposes; thus, the amounts of data enormous, and crude, heterogeneous, incomplete, largely unstructured, presenting challenges to effective analyses timely, reliable results. Particularly, research dealing with clinical notes relevant patient care outcome is seldom conducted, due complexity extraction accurate annotation in past. RECIST a set widely accepted criteria evaluate tumor response patients undergoing...
Abstract Background The plasma cell disorders (PCDs), multiple myeloma (MM), and light-chain amyloidosis (AL) are disproportionately diseases of older adults, whose care may be complicated by frailty associated with advancing age. We sought to evaluate the prevalence functional deficits symptoms in a cohort persons PCDs associations demographic, disease-related, functional, psychosocial measures quality life (QoL). Patients Methods Adults were recruited into an observational registry...